WO2002000878A3 - Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique - Google Patents
Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique Download PDFInfo
- Publication number
- WO2002000878A3 WO2002000878A3 PCT/FR2001/001999 FR0101999W WO0200878A3 WO 2002000878 A3 WO2002000878 A3 WO 2002000878A3 FR 0101999 W FR0101999 W FR 0101999W WO 0200878 A3 WO0200878 A3 WO 0200878A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- msp1
- isoforms
- human
- concerns
- therapeutic use
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 5
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 5
- 102000043859 Dynamin Human genes 0.000 title abstract 2
- 108700021058 Dynamin Proteins 0.000 title abstract 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 title 1
- 230000002438 mitochondrial effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 206010003694 Atrophy Diseases 0.000 abstract 2
- 230000037444 atrophy Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4722—G-proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention a pour objet une protéine humaine appartenant à la famille des dynamines, appelée MSP1, et ses 7 isoformes MSP1-X, dont les mutations sont en particulier responsables de l'atrophie optique dominante. La présente invention concerne également les séquences nucléotidiques codant ladite protéine, ses isoformes et leurs formes mutées, les vecteurs capables d'exprimer ladite protéine et ses isoformes ou leurs formes mutées, dans tout type de cellules hôtes, ainsi que les cellules transformées par lesdits vecteurs et les procédés les utilisant. L'invention a enfin pour objet des procédés d'identification de composés biologiques ou pharmacologiques modulant l'activité de la protéine d'identification de composés biologiques ou pharmacologiques modulant l'activité de la protéine et de ses isoformes selon l'invention et l'utilisation desdits composés pour la recherche et la fabrication de substances actives utiles en thérapie, en particulier pour la mise au point d'un traitement de l'atrophie optique dominante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR00/08140 | 2000-06-26 | ||
| FR0008140A FR2810673B1 (fr) | 2000-06-26 | 2000-06-26 | Dynamine mitochondriale humaine msp1 et son utilisation en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002000878A2 WO2002000878A2 (fr) | 2002-01-03 |
| WO2002000878A3 true WO2002000878A3 (fr) | 2003-04-24 |
Family
ID=8851656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2001/001999 WO2002000878A2 (fr) | 2000-06-26 | 2001-06-25 | Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2810673B1 (fr) |
| WO (1) | WO2002000878A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0023555D0 (en) * | 2000-09-26 | 2000-11-08 | Inst Of Ophthalmology | Improvements in and relating to treatments for eye disease |
| AU2003214048A1 (en) * | 2002-01-25 | 2003-09-02 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Proteins involved in the regulation of energy homeostasis and organelle metabolism |
| WO2007056435A2 (fr) * | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Maladies mediees par la dynamine et procedes et produits associes |
| US9144594B2 (en) | 2005-11-08 | 2015-09-29 | University Of Miami | Cathepsin L mediated diseases and associated methods and products |
| EP2030021B1 (fr) | 2006-05-18 | 2012-11-21 | Andreas Reichert | Procédé pour diagnostiquer un dysfonctionnement mitochondrial |
| CN111518897A (zh) * | 2019-02-01 | 2020-08-11 | 中国科学院广州生物医药与健康研究院 | 分子标志物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053312A1 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides |
-
2000
- 2000-06-26 FR FR0008140A patent/FR2810673B1/fr not_active Expired - Fee Related
-
2001
- 2001-06-25 WO PCT/FR2001/001999 patent/WO2002000878A2/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001053312A1 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides |
Non-Patent Citations (9)
| Title |
|---|
| ALEXANDER C ET AL: "OPA1, ENCODING A DYNAMIN-RELATED GTPASE, IS MUTATED IN AUTOSOMAL DOMINANT OPTIC ATROPHY LINKED TO CHROMOSOME 3Q28", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 26, no. 2, October 2000 (2000-10-01), pages 211 - 215, XP000993212, ISSN: 1061-4036 * |
| BROWN JEREMIAH JR ET AL: "Clinical and genetic analysis of a family affected with dominant optic atrophy (OPA1).", ARCHIVES OF OPHTHALMOLOGY, vol. 115, no. 1, 1997, pages 95 - 99, XP000993189, ISSN: 0003-9950 * |
| DATABASE EMBL [online] 10 April 1998 (1998-04-10), OHARA O ET AL: "Homo sapiens mRNA for KIAA0567 protein, partial cds.", XP002166490, Database accession no. AB011139 * |
| DATABASE EMBL [online] 22 October 2001 (2001-10-22), TANG Y T ET AL: "Human polynucleotide SEQ ID NO 731.", XP002203707, Database accession no. AAI58528 * |
| DATABASE EMBL [online] 22 October 2001 (2001-10-22), TANG Y T ET AL: "Human polypeptide SEQ ID NO 2517.", XP002203708, Database accession no. AAM39372 * |
| DELETTRE CECILE ET AL: "Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy.", NATURE GENETICS, vol. 26, no. 2, October 2000 (2000-10-01), pages 207 - 210, XP000993218, ISSN: 1061-4036 * |
| PESCH U E A ET AL: "Genomic structure of a retinal expressed candidate gene for dominant optic atrophy (Kjer type).", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 65, no. 4, October 1999 (1999-10-01), 49th Annual Meeting of the American Society of Human Genetics;San Francisco, California, USA; October 19-23, 1999, pages A378, XP000993287, ISSN: 0002-9297 * |
| PESCH ULRIKE E A ET AL: "OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance.", HUMAN MOLECULAR GENETICS, vol. 10, no. 13, 2001, pages 1359 - 1368, XP002203706, ISSN: 0964-6906 * |
| VAN DER BLIEK ALEXANDER M: "Functional diversity in the dynamin family.", TRENDS IN CELL BIOLOGY, vol. 9, no. 3, March 1999 (1999-03-01), pages 96 - 102, XP002203705, ISSN: 0962-8924 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2810673B1 (fr) | 2004-10-08 |
| WO2002000878A2 (fr) | 2002-01-03 |
| FR2810673A1 (fr) | 2001-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68929043D1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| AU2001254624A1 (en) | Human coagulation factor vii variants | |
| SI1641483T1 (sl) | Fuzijski proteini | |
| HUP0003533A2 (hu) | Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk | |
| WO2003103589A3 (fr) | Utilisation d'il-21 dans le traitement du cancer et dans d'autres applications therapeutiques | |
| HUP0203409A2 (hu) | Gamma-interferon-konjugátumok | |
| AU1724795A (en) | Human tissue inhibitor of metalloproteinase-4 | |
| AU5464000A (en) | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins | |
| NO960309L (no) | Agonister og antagonister for humaninterleukin-10 | |
| WO2004074486A3 (fr) | Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees | |
| NO20014537L (no) | AKT-nukleinsyrer, -polypeptider og anvendelse av disse | |
| WO2002000878A3 (fr) | Dynamine mitochondriale humaine msp1, ses isoformes msp1-x, et leur utilisation en therapeutique | |
| EP1281763A3 (fr) | FACTEUR DE TRANSCRIPTION "Early growth response-1" (EGR-1) | |
| ATE291586T1 (de) | Humanes antibiotisches protein | |
| WO2000008157A3 (fr) | Genes humains transporteurs d'anions atnov | |
| HUP9801681A2 (hu) | Mutáns proteinek | |
| DK1283214T3 (da) | Hidtil ukendte kollektiner | |
| WO2004113386A3 (fr) | Protéines d'hirudine modifiée et épitopes de lymphocytes t dans l'hirudine | |
| AU5327198A (en) | Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy | |
| KR100488038B1 (ko) | 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도 | |
| AU9743698A (en) | Allelic variant of human stat3 | |
| HUP0300813A2 (hu) | Gének, fehérjék és alkalmazásuk | |
| AU2459188A (en) | Anticoagulative protein pp4-x, and its preparation and use | |
| AU2003258550A1 (en) | Splicing-variant of the human p53 protein and use thereof in the production of pharmaceutical preparations for treating tumoural diseases | |
| WO2003040320A3 (fr) | Modulation par composes antisens de l'expression de la proteine 2 mediatrice de reaction de collapsine humaine (crmp) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |